Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis.
In a random, blind study, we compared the antithrombotic potential of unfractioned heparin, a low-molecular weight heparin (LMWH) and a recombinant hirudin (r-hirudin) given subcutaneously in a jugular vein thrombosis model in rabbits. All drugs and placebo were injected subcutaneously 2 h before inducing experimental thrombosis. A good thromboprophylactic effect was obtained with either LMWH and r-hirudin as compared with placebo. By contrast, no significant differences were found between groups in bleeding time. We also found a small (non-significant) prolongation of the activated partial thromboplastin time in the r-hirudin-treated animals. As for thrombin time, r-hirudin-treated rabbits exhibited too much sensitivity, with noncoagulable end-points. In our study, r-hirudin at the dose used seemed to be as effective as LMWH is in the prophylaxis of venous thrombosis.
Monreal
M
M
Experimental Unit on Thrombosis, Universidad Autónoma de Barcelona, Spain.
Galego
G
G
Monreal
L
L
Angles
A M
AM
Monasterio
J
J
Oller
B
B
D000818:Animals; D004311:Double-Blind Method; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D024764:Hirudin Therapy; D007601:Jugular Veins; D008297:Male; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D011994:Recombinant Proteins; D006493:Heparin